GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Personalis Inc (STU:04X) » Definitions » EV-to-EBIT

Personalis (STU:04X) EV-to-EBIT : -0.23 (As of May. 25, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Personalis EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Personalis's Enterprise Value is €19.49 Mil. Personalis's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-85.55 Mil. Therefore, Personalis's EV-to-EBIT for today is -0.23.

The historical rank and industry rank for Personalis's EV-to-EBIT or its related term are showing as below:

STU:04X' s EV-to-EBIT Range Over the Past 10 Years
Min: -45.25   Med: -2.62   Max: 2.91
Current: -0.22

During the past 7 years, the highest EV-to-EBIT of Personalis was 2.91. The lowest was -45.25. And the median was -2.62.

STU:04X's EV-to-EBIT is ranked worse than
100% of 103 companies
in the Medical Diagnostics & Research industry
Industry Median: 21.9 vs STU:04X: -0.22

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Personalis's Enterprise Value for the quarter that ended in Mar. 2024 was €23.71 Mil. Personalis's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-85.55 Mil. Personalis's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -360.74%.


Personalis EV-to-EBIT Historical Data

The historical data trend for Personalis's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Personalis EV-to-EBIT Chart

Personalis Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial -8.95 -30.07 -6.34 0.23 -0.37

Personalis Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.26 -0.03 0.13 -0.37 -0.30

Competitive Comparison of Personalis's EV-to-EBIT

For the Diagnostics & Research subindustry, Personalis's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Personalis's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Personalis's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Personalis's EV-to-EBIT falls into.



Personalis EV-to-EBIT Calculation

Personalis's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=19.493/-85.547
=-0.23

Personalis's current Enterprise Value is €19.49 Mil.
Personalis's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-85.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Personalis  (STU:04X) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Personalis's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-85.547/23.714286
=-360.74 %

Personalis's Enterprise Value for the quarter that ended in Mar. 2024 was €23.71 Mil.
Personalis's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-85.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Personalis EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Personalis's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Personalis (STU:04X) Business Description

Traded in Other Exchanges
Address
6600 Dumbarton Circle, Fremont, CA, USA, 94555
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Liquid Biopsy, NeXT Dx Test, and other Pharma Research Solutions.

Personalis (STU:04X) Headlines

No Headlines